Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
A MyMyelomaTeam Member asked a question 💭
Auckland, NZ
March 2
 · 
Reactions
A MyMyelomaTeam Member

My ratio is low when my myeloma is active. I am IgG lambda with 11:14 translocation and 17 p deletion. Your doctor will have to look at your full myeloma panel to see if you are still smoldering.

March 3
MyMyelomaTeam

What does a kappa lambda ratio of 0.02 mean in smoldering myeloma?

A kappa lambda ratio of 0.02 is significantly abnormal and indicates a severe imbalance in your light chain proteins. In smoldering myeloma, this very low ratio suggests your plasma cells are producing far more lambda light chains than kappa light chains.

Show Full Answer

What does a kappa lambda ratio of 0.02 mean in smoldering myeloma?

A kappa lambda ratio of 0.02 is significantly abnormal and indicates a severe imbalance in your light chain proteins. In smoldering myeloma, this very low ratio suggests your plasma cells are producing far more lambda light chains than kappa light chains.

This abnormal ratio is measured through a serum free light chain (SFLC) assay. A normal ratio typically falls between 0.26 and 1.65, so 0.02 is well outside the normal range.

In smoldering myeloma, having a high SFLC score (which includes an abnormal ratio like yours) is considered a risk factor for progression to active multiple myeloma. People with abnormal light chain ratios are more likely to develop full-blown myeloma compared to those with normal ratios.

This finding means:
- Your condition should be monitored closely
- You may be considered "high-risk" smoldering myeloma
- Your doctor might discuss early treatment options rather than watchful waiting
- Regular follow-up testing is important to catch any progression early

It's important to discuss these results with your healthcare team, as they can evaluate this finding alongside other factors like your M protein levels, plasma cell percentage, and any genetic markers to determine the best monitoring or treatment approach for your specific situation.

March 2

Related Questions

View All
A MyMyelomaTeam Member asked a question 💭
Auckland, NZ

Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In